These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
384 related articles for article (PubMed ID: 24998423)
1. Blood stream infections due to OXA-48-like carbapenemase-producing Enterobacteriaceae: treatment and survival. Balkan II; Aygün G; Aydın S; Mutcalı SI; Kara Z; Kuşkucu M; Midilli K; Şemen V; Aras S; Yemişen M; Mete B; Özaras R; Saltoğlu N; Tabak F; Öztürk R Int J Infect Dis; 2014 Sep; 26():51-6. PubMed ID: 24998423 [TBL] [Abstract][Full Text] [Related]
2. Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia. Tamma PD; Goodman KE; Harris AD; Tekle T; Roberts A; Taiwo A; Simner PJ Clin Infect Dis; 2017 Feb; 64(3):257-264. PubMed ID: 28013264 [TBL] [Abstract][Full Text] [Related]
3. National survey of colistin resistance among carbapenemase-producing Enterobacteriaceae and outbreak caused by colistin-resistant OXA-48-producing Klebsiella pneumoniae, France, 2014. Jayol A; Poirel L; Dortet L; Nordmann P Euro Surveill; 2016 Sep; 21(37):. PubMed ID: 27685838 [TBL] [Abstract][Full Text] [Related]
4. Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella. Huang SS; Lee MH; Leu HS J Microbiol Immunol Infect; 2006 Dec; 39(6):496-502. PubMed ID: 17164953 [TBL] [Abstract][Full Text] [Related]
5. Epidemiology of Carbapenem-Resistant Enterobacteriaceae Infections: Report from the China CRE Network. Zhang Y; Wang Q; Yin Y; Chen H; Jin L; Gu B; Xie L; Yang C; Ma X; Li H; Li W; Zhang X; Liao K; Man S; Wang S; Wen H; Li B; Guo Z; Tian J; Pei F; Liu L; Zhang L; Zou C; Hu T; Cai J; Yang H; Huang J; Jia X; Huang W; Cao B; Wang H Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203488 [TBL] [Abstract][Full Text] [Related]
6. Retrospective Observational Study from a Chinese Network of the Impact of Combination Therapy versus Monotherapy on Mortality from Carbapenem-Resistant Wang X; Wang Q; Cao B; Sun S; Zhang Y; Gu B; Li B; Liao K; Zhao F; Jin L; Jin C; Yang C; Pei F; Zhang Z; Wang H Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30348660 [TBL] [Abstract][Full Text] [Related]
7. Does Quick Sepsis-Related Organ Failure Assessment Suggest the Use of Initial Empirical Carbapenem Therapy in Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Bacteria? :A Multicenter Case-Control Study. Mitsuboshi S; Tsuruma N; Watanabe K; Takahashi S; Nakashita M; Ito A; Kobayashi K; Tsugita M Jpn J Infect Dis; 2019 Mar; 72(2):124-126. PubMed ID: 30381688 [TBL] [Abstract][Full Text] [Related]
8. Over-treatment of carbapenemase-producing Enterobacteriaceae. Rihani DS; Wallace MR; Sieger BE; Waite RA; Fox M; Brown SA; Deryke CA Scand J Infect Dis; 2012 May; 44(5):325-9. PubMed ID: 22200121 [TBL] [Abstract][Full Text] [Related]
9. Clinical and Microbiological Analysis of Risk Factors for Mortality in Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia. Seo H; Lee SC; Chung H; Ra SH; Sung H; Kim MN; Jung J; Kim MJ; Kim SH; Lee SO; Choi SH; Kim YS; Woo JH; Chong YP Int J Antimicrob Agents; 2020 Oct; 56(4):106126. PubMed ID: 32755654 [TBL] [Abstract][Full Text] [Related]
10. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia. Tamma PD; Han JH; Rock C; Harris AD; Lautenbach E; Hsu AJ; Avdic E; Cosgrove SE; Clin Infect Dis; 2015 May; 60(9):1319-25. PubMed ID: 25586681 [TBL] [Abstract][Full Text] [Related]
11. Factors associated to prevalence and treatment of carbapenem-resistant Enterobacteriaceae infections: a seven years retrospective study in three tertiary care hospitals. Pang F; Jia XQ; Zhao QG; Zhang Y Ann Clin Microbiol Antimicrob; 2018 Mar; 17(1):13. PubMed ID: 29571291 [TBL] [Abstract][Full Text] [Related]
12. Mortality factors and antibiotic options in carbapenem-resistant Enterobacterales bloodstream infections: Insights from a high-prevalence setting with co-occurring NDM-1 and OXA-48. Karnmueng P; Montakantikul P; Paiboonvong T; Plongla R; Chatsuwan T; Chumnumwat S Clin Transl Sci; 2024 Jun; 17(6):e13855. PubMed ID: 38853376 [TBL] [Abstract][Full Text] [Related]
13. Epidemiological, clinical, and microbiological characteristics of carbapenemase-producing Enterobacteriaceae bloodstream infection in the Republic of Korea. Park JW; Lee H; Park SY; Kim TH Antimicrob Resist Infect Control; 2019; 8():48. PubMed ID: 30873279 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of β-Lactam/β-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia. Gudiol C; Royo-Cebrecos C; Abdala E; Akova M; Álvarez R; Maestro-de la Calle G; Cano A; Cervera C; Clemente WT; Martín-Dávila P; Freifeld A; Gómez L; Gottlieb T; Gurguí M; Herrera F; Manzur A; Maschmeyer G; Meije Y; Montejo M; Peghin M; Rodríguez-Baño J; Ruiz-Camps I; Sukiennik TC; Tebe C; Carratalà J; Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584145 [TBL] [Abstract][Full Text] [Related]
15. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Tumbarello M; Sanguinetti M; Montuori E; Trecarichi EM; Posteraro B; Fiori B; Citton R; D'Inzeo T; Fadda G; Cauda R; Spanu T Antimicrob Agents Chemother; 2007 Jun; 51(6):1987-94. PubMed ID: 17387156 [TBL] [Abstract][Full Text] [Related]
16. Bloodstream infections caused by metallo-β-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes. Mouloudi E; Protonotariou E; Zagorianou A; Iosifidis E; Karapanagiotou A; Giasnetsova T; Tsioka A; Roilides E; Sofianou D; Gritsi-Gerogianni N Infect Control Hosp Epidemiol; 2010 Dec; 31(12):1250-6. PubMed ID: 20973725 [TBL] [Abstract][Full Text] [Related]
17. The impact of colistin-based regimens on mortality compared to other antimicrobials in patients with carbapenem-resistant Enterobacterales bacteremia in South African hospitals: a cross-sectional study. Ngoma N; Perovic O; de Voux A; Musekiwa A; Shuping L; BMC Infect Dis; 2024 Jun; 24(1):561. PubMed ID: 38840122 [TBL] [Abstract][Full Text] [Related]
18. [Infectious diseases caused by carbapenemase-producing Enterobacteriaceae--a particular challenge for antibacterial therapy]. Stock I Med Monatsschr Pharm; 2014 May; 37(5):162-72; quiz 173-4. PubMed ID: 24908928 [TBL] [Abstract][Full Text] [Related]
19. Clonal emergence of Klebsiella pneumoniae ST14 co-producing OXA-48-type and NDM carbapenemases with high rate of colistin resistance in Dubai, United Arab Emirates. Moubareck CA; Mouftah SF; Pál T; Ghazawi A; Halat DH; Nabi A; AlSharhan MA; AlDeesi ZO; Peters CC; Celiloglu H; Sannegowda M; Sarkis DK; Sonnevend Á Int J Antimicrob Agents; 2018 Jul; 52(1):90-95. PubMed ID: 29530587 [TBL] [Abstract][Full Text] [Related]
20. Non-intravenous carbapenem-sparing antibiotics for definitive treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamase (ESBL) or AmpC β-lactamase: A propensity score study. Meije Y; Pigrau C; Fernández-Hidalgo N; Clemente M; Ortega L; Sanz X; Loureiro-Amigo J; Sierra M; Ayestarán A; Morales-Cartagena A; Ribera A; Duarte A; Abelenda G; Rodríguez-Baño J; Martínez-Montauti J Int J Antimicrob Agents; 2019 Aug; 54(2):189-196. PubMed ID: 31075401 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]